Sunshine Cash Conversion Cycle vs Price Cash Flow Ratio Analysis

SBFM Stock

USD 3.04 0.60 24.59%

Sunshine Biopharma financial indicator trend analysis is much more than just breaking down Sunshine Biopharma prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Sunshine Biopharma is a good investment. Please check the relationship between Sunshine Biopharma Cash Conversion Cycle and its Price Cash Flow Ratio accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sunshine Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census.

To learn how to invest in Sunshine Stock, please use our How to Invest in Sunshine Biopharma guide.

Cash Conversion Cycle vs Price Cash Flow Ratio

Cash Conversion Cycle vs Price Cash Flow Ratio Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Sunshine Biopharma Cash Conversion Cycle account and Price Cash Flow Ratio. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Sunshine Biopharma's Cash Conversion Cycle and Price Cash Flow Ratio is -0.19. Overlapping area represents the amount of variation of Cash Conversion Cycle that can explain the historical movement of Price Cash Flow Ratio in the same time period over historical financial statements of Sunshine Biopharma, assuming nothing else is changed. The correlation between historical values of Sunshine Biopharma's Cash Conversion Cycle and Price Cash Flow Ratio is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash Conversion Cycle of Sunshine Biopharma are associated (or correlated) with its Price Cash Flow Ratio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Price Cash Flow Ratio has no effect on the direction of Cash Conversion Cycle i.e., Sunshine Biopharma's Cash Conversion Cycle and Price Cash Flow Ratio go up and down completely randomly.

Correlation Coefficient

-0.19

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Cash Conversion Cycle

Price Cash Flow Ratio

Most indicators from Sunshine Biopharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Sunshine Biopharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sunshine Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census.

To learn how to invest in Sunshine Stock, please use our How to Invest in Sunshine Biopharma guide.At this time, Sunshine Biopharma's Selling General Administrative is very stable compared to the past year. As of the 27th of November 2024, Tax Provision is likely to grow to about 428.6 K, though Issuance Of Capital Stock is likely to grow to (8.6 M).

	2021	2022	2023	2024 (projected)
Other Operating Expenses	2.7M	13.0M	28.9M	30.3M
Interest Expense	328.8K	39.4K	137.3K	148.9K

Other Operating Expenses Interest Expense

Sunshine Biopharma fundamental ratios Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Short Long Term Debt Total	Other Current Liab	Other Assets	Other Current Assets	Short Term Debt	Net Tangible Assets	Short Long Term Debt	Property Plant And Equipment Net	Non Current Assets Total	Net Receivables	Inventory	Intangible Assets
Total Assets		0.98	1.0	-0.99	-0.94	1.0	0.99	0.99	0.04	0.1	0.97	0.97	1.0	-0.28	0.53	0.85	0.32	0.99	0.35	0.43	0.86	0.99	0.92	0.98	0.96	0.54
Total Current Liabilities	0.98		0.97	-0.97	-0.93	0.98	0.98	0.98	0.11	0.12	0.95	0.98	0.98	-0.23	0.61	0.79	0.34	0.96	0.44	0.29	0.82	0.98	0.88	0.95	0.91	0.52
Total Stockholder Equity	1.0	0.97		-1.0	-0.92	1.0	0.99	0.99	0.04	0.05	0.96	0.96	1.0	-0.29	0.48	0.86	0.3	0.99	0.31	0.46	0.84	0.99	0.93	0.99	0.96	0.52
Net Debt	-0.99	-0.97	-1.0		0.92	-0.99	-0.99	-0.99	-0.03	-0.05	-0.95	-0.96	-1.0	0.29	-0.52	-0.82	-0.28	-0.98	-0.36	-0.48	-0.83	-0.98	-0.91	-0.97	-0.94	-0.52
Retained Earnings	-0.94	-0.93	-0.92	0.92		-0.93	-0.93	-0.93	-0.15	-0.35	-0.99	-0.97	-0.94	0.21	-0.6	-0.82	-0.43	-0.93	-0.43	-0.34	-0.95	-0.93	-0.78	-0.92	-0.91	-0.59
Accounts Payable	1.0	0.98	1.0	-0.99	-0.93		0.99	0.99	0.07	0.07	0.97	0.97	1.0	-0.28	0.52	0.84	0.32	0.99	0.34	0.42	0.84	0.99	0.92	0.98	0.96	0.53
Cash	0.99	0.98	0.99	-0.99	-0.93	0.99		1.0	0.03	0.12	0.96	0.98	0.99	-0.28	0.61	0.78	0.29	0.97	0.45	0.43	0.85	0.98	0.88	0.95	0.91	0.5
Cash And Short Term Investments	0.99	0.98	0.99	-0.99	-0.93	0.99	1.0		0.03	0.12	0.96	0.98	0.99	-0.28	0.61	0.78	0.29	0.97	0.45	0.43	0.85	0.98	0.88	0.95	0.91	0.5
Common Stock Shares Outstanding	0.04	0.11	0.04	-0.03	-0.15	0.07	0.03	0.03		0.1	0.12	0.07	0.04	-0.05	0.02	0.07	0.17	0.04	0.03	-0.23	0.05	0.09	-0.05	0.06	0.06	0.22
Non Current Liabilities Total	0.1	0.12	0.05	-0.05	-0.35	0.07	0.12	0.12	0.1		0.26	0.27	0.1	-0.2	0.53	0.04	0.26	0.09	0.54	-0.28	0.53	0.04	-0.11	0.05	0.05	0.22
Other Stockholder Equity	0.97	0.95	0.96	-0.95	-0.99	0.97	0.96	0.96	0.12	0.26		0.98	0.97	-0.25	0.56	0.85	0.4	0.97	0.38	0.39	0.94	0.96	0.85	0.96	0.95	0.57
Total Liab	0.97	0.98	0.96	-0.96	-0.97	0.97	0.98	0.98	0.07	0.27	0.98		0.97	-0.25	0.68	0.77	0.36	0.95	0.51	0.31	0.9	0.96	0.84	0.93	0.9	0.56
Total Current Assets	1.0	0.98	1.0	-1.0	-0.94	1.0	0.99	0.99	0.04	0.1	0.97	0.97		-0.28	0.53	0.84	0.31	0.99	0.36	0.44	0.86	0.99	0.91	0.98	0.95	0.53
Common Stock	-0.28	-0.23	-0.29	0.29	0.21	-0.28	-0.28	-0.28	-0.05	-0.2	-0.25	-0.25	-0.28		-0.1	-0.24	0.11	-0.29	-0.08	-0.4	-0.28	-0.27	-0.42	-0.27	-0.27	-0.4
Short Long Term Debt Total	0.53	0.61	0.48	-0.52	-0.6	0.52	0.61	0.61	0.02	0.53	0.56	0.68	0.53	-0.1		0.08	0.22	0.46	0.95	-0.02	0.59	0.53	0.26	0.38	0.3	0.23
Other Current Liab	0.85	0.79	0.86	-0.82	-0.82	0.84	0.78	0.78	0.07	0.04	0.85	0.77	0.84	-0.24	0.08		0.35	0.89	-0.13	0.36	0.77	0.82	0.87	0.93	0.96	0.58
Other Assets	0.32	0.34	0.3	-0.28	-0.43	0.32	0.29	0.29	0.17	0.26	0.4	0.36	0.31	0.11	0.22	0.35		0.34	0.13	-0.07	0.38	0.32	0.24	0.33	0.34	0.2
Other Current Assets	0.99	0.96	0.99	-0.98	-0.93	0.99	0.97	0.97	0.04	0.09	0.97	0.95	0.99	-0.29	0.46	0.89	0.34		0.28	0.45	0.86	0.97	0.92	0.99	0.97	0.56
Short Term Debt	0.35	0.44	0.31	-0.36	-0.43	0.34	0.45	0.45	0.03	0.54	0.38	0.51	0.36	-0.08	0.95	-0.13	0.13	0.28		-0.02	0.45	0.36	0.09	0.19	0.1	0.1
Net Tangible Assets	0.43	0.29	0.46	-0.48	-0.34	0.42	0.43	0.43	-0.23	-0.28	0.39	0.31	0.44	-0.4	-0.02	0.36	-0.07	0.45	-0.02		0.34	0.44	0.49	0.43	0.42	0.14
Short Long Term Debt	0.86	0.82	0.84	-0.83	-0.95	0.84	0.85	0.85	0.05	0.53	0.94	0.9	0.86	-0.28	0.59	0.77	0.38	0.86	0.45	0.34		0.82	0.71	0.84	0.84	0.58
Property Plant And Equipment Net	0.99	0.98	0.99	-0.98	-0.93	0.99	0.98	0.98	0.09	0.04	0.96	0.96	0.99	-0.27	0.53	0.82	0.32	0.97	0.36	0.44	0.82		0.93	0.97	0.94	0.54
Non Current Assets Total	0.92	0.88	0.93	-0.91	-0.78	0.92	0.88	0.88	-0.05	-0.11	0.85	0.84	0.91	-0.42	0.26	0.87	0.24	0.92	0.09	0.49	0.71	0.93		0.94	0.93	0.55
Net Receivables	0.98	0.95	0.99	-0.97	-0.92	0.98	0.95	0.95	0.06	0.05	0.96	0.93	0.98	-0.27	0.38	0.93	0.33	0.99	0.19	0.43	0.84	0.97	0.94		0.99	0.56
Inventory	0.96	0.91	0.96	-0.94	-0.91	0.96	0.91	0.91	0.06	0.05	0.95	0.9	0.95	-0.27	0.3	0.96	0.34	0.97	0.1	0.42	0.84	0.94	0.93	0.99		0.58
Intangible Assets	0.54	0.52	0.52	-0.52	-0.59	0.53	0.5	0.5	0.22	0.22	0.57	0.56	0.53	-0.4	0.23	0.58	0.2	0.56	0.1	0.14	0.58	0.54	0.55	0.56	0.58

Click cells to compare fundamentals

Sunshine Biopharma Account Relationship Matchups

Sunshine Biopharma fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	98.1K	1.0M	2.2M	29.2M	27.3M	28.7M
Total Current Liabilities	833.5K	1.1M	91.2K	6.9M	5.6M	5.8M
Total Stockholder Equity	(735.4K)	(954.8K)	211.7K	21.6M	21.2M	22.3M
Net Debt	675.1K	923.2K	(145.2K)	(17.6M)	(15.6M)	(14.9M)
Retained Earnings	(17.4M)	(20.2M)	(32.7M)	(59.4M)	(63.9M)	(60.7M)
Accounts Payable	96.9K	62.9K	42.9K	2.8M	2.6M	2.7M
Cash	40.5K	989.9K	2.0M	21.8M	16.3M	17.1M
Cash And Short Term Investments	40.5K	989.9K	2.0M	21.8M	16.3M	17.1M
Common Stock Shares Outstanding	54.7K	866.0	1.3K	7.6K	12.2K	8.8K
Liabilities And Stockholders Equity	98.1K	1.0M	2.2M	29.2M	27.3M	28.7M
Non Current Liabilities Total	812.5K	949.0K	1.9M	685.3K	587.8K	480.3K
Other Stockholder Equity	16.6M	19.2M	32.8M	80.8M	84.4M	88.6M
Total Liab	833.5K	2.0M	2.0M	7.6M	6.1M	6.4M
Total Current Assets	65.7K	1.0M	2.2M	27.3M	24.9M	26.1M
Common Stock	35.3K	346.4K	2.6K	22.6K	28.0K	26.6K
Short Long Term Debt Total	715.6K	1.9M	1.9M	4.3M	657.7K	1.0M
Other Current Liab	21.1K	24.3K	48.3K	496.2K	2.5M	2.7M
Other Current Assets	8.8K	10.4K	37.2K	283.8K	310.6K	326.1K
Short Term Debt	715.6K	964.1K	1.9M	3.8M	118.7K	112.7K
Net Tangible Assets	(105.8K)	(785.4K)	(1.1M)	111.7K	100.5K	105.5K
Short Long Term Debt	662.8K	715.6K	964.1K	3.6M	4.2M	4.4M
Property Plant And Equipment Net	32.5K	19.5K	7.1K	1.2M	1.0M	1.1M
Non Current Assets Total	32.5K	19.5K	7.1K	1.9M	2.5M	2.6M
Net Receivables	430.0	1.9K	7.8K	1.9M	2.6M	2.7M
Accumulated Other Comprehensive Income	(2.5K)	(2.9K)	(23.1K)	161.8K	696.1K	730.9K
Property Plant Equipment	45.1K	32.5K	19.5K	7.1K	8.1K	7.7K
Non Currrent Assets Other	(32.5K)	(19.5K)	(7.1K)	(1.9M)	(1.7M)	(1.7M)
Net Invested Capital	(69.8K)	858.3K	2.0M	25.3M	21.2M	22.3M
Net Working Capital	(767.8K)	(25.4K)	2.1M	20.4M	19.3M	20.3M
Capital Stock	85.3K	446.4K	102.6K	23.6K	29.0K	27.6K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Sunshine Biopharma is a strong investment it is important to analyze Sunshine Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Sunshine Biopharma's future performance. For an informed investment choice regarding Sunshine Stock, refer to the following important reports:

How To Invest In Sunshine

Details

Is Sunshine Stock a good investment?

Details

What is Sunshine Biopharma's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sunshine Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census.

To learn how to invest in Sunshine Stock, please use our How to Invest in Sunshine Biopharma guide.

You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sunshine Biopharma. If investors know Sunshine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sunshine Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(127.90)

Revenue Per Share

197.42

Quarterly Revenue Growth

0.416

Return On Assets

(0.11)

Return On Equity

(0.18)

The market value of Sunshine Biopharma is measured differently than its book value, which is the value of Sunshine that is recorded on the company's balance sheet. Investors also form their own opinion of Sunshine Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Sunshine Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sunshine Biopharma's market value can be influenced by many factors that don't directly affect Sunshine Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Sunshine Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sunshine Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sunshine Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Sunshine Cash Conversion Cycle vs Price Cash Flow Ratio Analysis

Cash Conversion Cycle vs Price Cash Flow Ratio

Cash Conversion Cycle vs Price Cash Flow Ratio Correlation Analysis

Correlation Coefficient

Cash Conversion Cycle

Price Cash Flow Ratio

Sunshine Biopharma fundamental ratios Correlations

Sunshine Biopharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Sunshine Biopharma fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Accounts Payable	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Accounts Payable	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Accounts Payable

Total Current Assets	- 1.0	Net Debt
Net Debt	- 1.0	Total Stockholder Equity
Other Stockholder Equity	- 0.99	Retained Earnings
Cash And Short Term Investments	- 0.99	Net Debt
Cash	- 0.99	Net Debt
Accounts Payable	- 0.99	Net Debt